NetSuite QuickStart helps automate routine financial work in the background so founders can focus on building and growing their businesses

AUSTIN, Texas, Oct. 14, 2026 /PRNewswire/ -- Oracle NetSuite, the #1 AI Cloud ERP, today announced the availability of NetSuite QuickStart, a free AI-first financial platform built for early-stage technology startups. QuickStart enables founders to establish a strong financial foundation within minutes. Embedded AI and teams of AI agents help founders build their business by automating accounting, banking, accounts receivable, accounts payable, and subscription management and by proactively surfacing key insights like software industry metrics. Built to grow with startups, QuickStart works with the AI tools founders already use and provides a natural path to NetSuite as their businesses scale.

"As a technology founder, I know from experience that building a company shouldn't mean becoming a finance expert," said Evan Goldberg, founder and executive vice president, Oracle NetSuite. "QuickStart is designed to handle more of the routine financial work, surface what actually needs a founder's judgment, and provide a financial foundation that can grow with the business, making NetSuite the first and last business system they will ever need."

QuickStart uses AI to handle more of the routine financial work so founders can spend more time building their businesses. With Ask Oracle built into the platform, founders can use a conversational AI assistant to ask questions, analyze business data, surface insights, and take action using trusted information. Through Model Context Protocol (MCP), founders can engage with trusted data in QuickStart via the AI tools they already use, including Claude and ChatGPT. Key capabilities include:

- AI-first financial management: Helps founders establish a strong financial foundation and leverage AI to manage day-to-day finances, including accounting, banking, accounts receivable, accounts payable, and other essential financial workflows.

- AI-powered insights and automation: Helps founders spend less time on routine accounting by providing relevant financial insights and autonomous capabilities to import, match, categorize, and reconcile bank transactions from connected bank and credit card accounts.

- Industry-specific financial capabilities: Helps founders monitor business performance and make informed decisions with built-in SaaS and startup financial metrics, including monthly recurring revenue (MRR), burn rate, and runway, as well as capabilities to manage subscriptions and online payments, generate reports, and integrate with tools commonly used across the technology startup ecosystem.

- AI tool integration: Helps founders stay informed and act on financial decisions within the AI tools they already use, including ChatGPT and Claude, by providing access to trusted QuickStart financial data and capabilities via MCP.

- Fast, self-service setup: Helps founders avoid a traditional implementation process and establish financial operations quickly with an AI-powered self-service setup. Users can connect a bank account, create their first invoice, and begin viewing financials in less than 10 minutes, and tailor the system to their business.

- Enterprise-grade foundation: Helps founders automate financial work and support business growth with Oracle's enterprise-grade database, cloud infrastructure, and embedded AI.

As startups grow, QuickStart provides a seamless and automated path to NetSuite, enabling them to expand operations and meet more sophisticated financial needs without disruption or starting over.

"From early days, we knew we needed an AI-native financial platform to enable us to stay laser focused on our mission," said James Salanitri, founder and CEO of Contender AI. "With NetSuite QuickStart, we quickly established the financial foundation we needed without a complicated setup process. AI helps manage routine accounting work, giving us greater visibility into our financials and enabling our small team to focus on growing the business."

"The next generation of founders increasingly expects AI to automate routine financial and administrative work so teams can stay focused on building the business," said Charles Brennan, principal analyst, Nucleus Research. "For technology startups, the value of this approach is less about adding more software and more about establishing financial discipline early, reducing manual work, and having an ERP environment that can support greater operational complexity as the business scales."

Availability: 

NetSuite QuickStart is available for free to eligible early-stage technology startups in the United States, subject to the QuickStart Terms of Use and Service*. See netsuite.com/quickstart for details.

*Usage limits include 2,500 new business records (including invoices and other transaction records), 800 emails, and 175 new documents per month. 20 GB of document storage, four connected bank and credit card accounts, and two concurrent integration requests - including MCP requests.

About Oracle NetSuite

For more than 28 years, Oracle NetSuite has helped organizations of all sizes reach their goals faster and more efficiently. NetSuite provides an integrated business system with embedded AI that delivers powerful financial management, supply chain, customer experience, and HR capabilities. Relied on by more than 44,000 customers in 220 countries and dependent territories, NetSuite is the #1 AI cloud enterprise resource planning (ERP) solution.

Trademarks

Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company - ushering in the new era of cloud computing.

SOURCE Oracle NetSuite

Share this article

Spinnaker Support Names Mark Fetches Global Chief Technology Officer

Expanded Role Unites Regional CTOs, Solution Consulting and Technical Account Management in One Global Organization

DENVER, Oct. 14, 2026 /PRNewswire/ -- Spinnaker Support, the third-party software support leader entrusted by 1,300+ global clients, today announced the promotion of Mark Fetches to Global Chief Technology Officer (CTO). In the expanded role, Fetches brings the company's regional CTOs, solution consulting team and technical account managers (TAMs) together into a single global organization. He will report to Chief Revenue Officer Pete Castello and join Spinnaker's Go-to-Market Leadership Team, strengthening the connection between customer business priorities and Spinnaker's technical sales and advisory capabilities.

"Customers choose Spinnaker for the expertise of our people," said Matt Stava, CEO of Spinnaker Support. "Mark showed in EMEA how much customers value close technical engagement from the start. With him leading these teams globally, we can bring that same level of guidance to every region, helping customers solve immediate challenges and plan for what comes next."

The new structure connects the technical guidance customers receive during evaluation with the expertise they rely on throughout their relationship with Spinnaker. Solution consultants who assess Oracle, SAP, VMware or PostgreSQL environments will now work alongside the TAMs and regional technology leaders who guide customers after the engagement begins. Iain Saunderson, chief technology officer for the Americas, will report to Fetches. Phil Wilkins, technical account manager and enterprise technical architect, and Sree Sakamuri, director of solution consulting, will also join Fetches' organization.

Fetches previously served as Spinnaker's CTO for EMEA, where he strengthened technical engagement with clients and connected their business priorities with Spinnaker's capabilities. He brings more than 30 years of technology consulting and leadership experience from Accenture, Deloitte, and PwC. In those roles, he led customer-facing technical teams and advised C-suite executives and boards on digital, cloud, AI and enterprise transformation programs. Fetches is based in the UK and holds TOGAF and ITIL certifications.

"The best time to talk about modernization is before an upgrade or renewal forces the issue," said Fetches. "That's when customers have the greatest freedom to evaluate their options and move forward on their own terms. By bringing together our regional CTOs, solution consultants and technical account managers, we give customers access to the right expertise from the first conversation through execution."

The promotion comes amid double-digit growth for Spinnaker, as more enterprises turn to independent support for greater control and flexibility. It follows several leadership appointments in 2026, including Rex Young as chief information officer in August and Vivek Pruthi as managing director for APAC. Spinnaker also promoted Martin Biggs to vice president and general manager of its PostgreSQL practice alongside the September launch of new PostgreSQL offerings to help enterprises reduce Oracle database dependency.

Resources:

- When AI Doesn't Understand Your ERP

- How Madrilena Gas Ensured Stability and Savings with Spinnaker

- How Telkom Turned Oracle Support Savings into Digital Investment

- How a National Telecommunications Provider Stabilized Critical Systems and Reset Its IT Strategy

About Spinnaker Support

Spinnaker Support delivers independent third-party support and expert services for Oracle, SAP, VMware, and PostgreSQL environments. Its support, maintenance and modernization services help organizations run, optimize and transform their enterprise technology environments. It empowers customers to reduce vendor dependency and align technology strategies with business objectives. Spinnaker Support is trusted worldwide, including in highly regulated industries, giving organizations greater choice, control, and flexibility to unlock long-term value and transformation. For more information: www.spinnakersupport.com. Follow Spinnaker on LinkedIn.

SOURCE Spinnaker Support LLC

Share this article

Zipline Launches ZipCoach to Bring Top-Store Performance to Every Location

New AI performance optimization engine identifies what drives business results at scale giving field leaders personalized, per-store recommendations and coaching actions to drive revenue across the fleet.

SAN FRANCISCO, Oct. 14, 2026 /PRNewswire/ -- Zipline, the Intelligent Frontline Operating System, today announced the launch of ZipCoach, a new embedded AI capability that enables intelligent store operations by turning store-specific data into clear coaching actions that improve business performance. ZipCoach replaces guesswork with certainty, insight with immediate action, and transforms one-off wins with fleet-wide, compounding improvement at every store.

ZipCoach connects frontline and operational behaviors, external variables, and business outcomes to learn what drives success for each individual store. It identifies timely improvement opportunities unique to every store and delivers personalized guidance at scale, helping field leaders and store managers continuously coach more effectively, focus on the actions that matter most, and improve execution.

"Every brand has a performance bell curve across its fleet: A handful of stores execute brilliantly, a few struggle, and most sit somewhere in the middle," said Melissa Wong, CEO and Co-Founder of Zipline. "The gap isn't necessarily talent, but historical knowledge, context, and knowing what to do next. We built ZipCoach to bring what your best stores know to every store, so you can shift the whole curve and transform your business."

With ZipCoach, organizations can:

- Get to the root of performance gaps: Identify the factors driving growth at each store using 300+ performance, operational, and behavioral data signals across the business.

- Know the next coaching action for every store: Give field leaders prioritized, personalized action plans they can implement in one click in Zipline.

- Continuously optimize their stores: Learn from every action and its impact, and get smarter recommendations over time.

"Zipline is already our teams' frontline operating system for communication, learning, and sales enablement tools," said Ryan Holm, DVP of Retail Innovation and Operations at Helzberg. "By connecting the behavioral data inside Zipline with our actual store KPIs, ZipCoach surfaces daily, clear, actionable suggestions for our field leaders, right inside the tool they're already using. It gives us visibility into the root causes of underperformance in our stores early, empowering our field teams to step in and fix the behavior before it impacts our results."

ZipCoach brings performance insights directly into the daily workflows where frontline teams already communicate, manage tasks, and learn. Because recommendations can be put into practice through Zipline, organizations can move from insight to execution without adding another system to their operations. As actions are taken and measured, ZipCoach helps organizations understand what works, improve execution, and scale best practices across the fleet.

ZipCoach is an embedded capability within the Zipline Intelligent Frontline Operating System and a building block for intelligent store operations and tasks. Brands interested in leveraging ZipCoach can learn more at getzipline.com/zipcoach.

About Zipline

Zipline is an Intelligent Frontline Operating System that continuously optimizes performance across multi-location businesses by empowering teams with better context, clearer priorities, and the knowledge to act. Trusted by more than 150 leading global brands—including Sephora, The Fresh Market, and American Eagle Outfitters—Zipline brings communications, tasks, knowledge, learning, and performance insights together in one trusted system. It helps frontline teams become effective from day one, gives leaders relevant visibility and actionable coaching recommendations, and helps every location improve execution, customer experience, and business performance. Every shift on Zipline makes every location better. Zipline has an NPS of 89 and a 4.9/5 customer satisfaction rating. To learn more, visit getzipline.com and follow Zipline on LinkedIn.

SOURCE Zipline

Share this article

Second console-free cryoprobe connects directly to shorter bronchoscopes and optimizes probe positioning control

MENLO PARK, Calif., Oct. 14, 2026/PRNewswire/ -- Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, has augmented its console-free cryoprobe portfolio. Today the company announced that the U.S. Food and Drug Administration granted 510(k) clearance on September 2, 2026, to the Maverix Narwhal™ Pro Cryo System, the second of two flexible cryoprobes built on the same cartridge-powered architecture.

Like the Narwhal Cryoprobe, cleared June 30, 2026, the Narwhal Pro Cryoprobe is powered by a single-use N₂O cartridge, allowing the fully disposable system to be used without purchasing or servicing a cryosurgical console. It also has a similar sharp, radiopaque tip and is compatible with bronchoscopes with a working channel inner diameter of 2 mm or larger. Narwhal Pro's working length, however, is optimized for shorter bronchoscopes that are 600 mm or shorter, and it includes adapters to connect directly with Olympus, Fuji, and Pentax scopes. It also features sheath and probe advancement handle controls for precise cryoprobe placement.

The Maverix Narwhal Pro Cryoprobe is indicated for palliative devitalization (destruction) of tissue during interventional procedures by the application of extreme cold and cryo-adhesion, for applications such as the removal of foreign bodies, mucus plugs, blood clots, necrotic tissue, tissue tumors (palliative recanalization) and tissue biopsies.

A growing evidence base for cryobiopsy

The FROSTBITE-2 study recently published in JAMA showed a 10% increase in diagnostic yield with a 1.1 mm cryoprobe over forceps transbronchial biopsy,¹ highlighting the modality's potential diagnostic value.

"With high-quality randomized data now demonstrating the advantages of cryobiopsy, our priority was making sure physicians have a cryoprobe built for the most commonly used endoscopes," said Jeremy Durack, MD, Chief Medical Officer at Maverix Medical. "We designed Narwhal and Narwhal Pro as a pair. The Pro is tailored to shorter scopes and mounts directly with supplied adapters, allowing the physician to set how far the sheath extends and better control cryoprobe advancement."

Probe comparison

Specifications per the Instructions for Use. Package contents: probe and biopsy scraper (sterile); Narwhal Pro also includes Olympus/Fuji/Pentax scope adapters (sterile). Cryo Cartridge supplied separately, shared by both probes.

"Cryobiopsy has become one of my preferred methods for acquiring tissue, and I want it available on the scope I have already chosen for the case, rather than planning the case around the probe," said Krish Bhadra, MD, Clinical Assistant Professor at Stanford Medicine.² "This additional probe option means I can choose cryo in more of my cases."

"Clearing two cryoprobes in nine weeks shows what this team can do," said Carla Jung, Chief Executive Officer of Maverix Medical. "We wanted to make cryobiopsy available in more cases, so we challenged the team to build a portfolio that needs no capital equipment, has a sharp tip, and adapts to different procedures. Narwhal and Narwhal Pro deliver on that."

The Narwhal Cryo System and Narwhal Pro Cryo System are expected to be broadly available in the United States in 2027, distributed by Thoracent, a Maverix company. Contact a Thoracent representative for ordering information.

The Narwhal Cryo System (K261068) and Narwhal Pro Cryo System (K262420) are FDA cleared but not yet commercially distributed. Rx only.

Footnotes

- Thiboutot J, et al. Cryobiopsy vs Forceps for Bronchoscopic Lung Biopsy: The FROSTBITE-2 Randomized Clinical Trial. JAMA. 2026; doi:10.1001/jama.2026.7908.

- Dr. Bhadra is a paid consultant to Maverix Medical.

About Maverix Medical

Maverix Medical aims to improve and save lives by revolutionizing the diagnosis and treatment of lung cancer. We seek to bring cutting-edge technologies to lung cancer care, empowering clinicians to diagnose lung cancer earlier and treat patients more effectively.

SOURCE Maverix Medical

Share this article

Innventure, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INV

NEW YORK, Oct. 14, 2026/PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Innventure, Inc. ("Innventure" or "the Company") (NASDAQ: INV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of INV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: November 17, 2025 to August 13, 2026

DEADLINE: October 27, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Innventure's Accelsius entered into a data center contract with DarkNX that was not likely to achieve actual revenue. Based on these facts, Innventure's public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

David J. Schwartz

DJS Law Group

274 White Plains Road, Suite 1

Eastchester, NY 10709

Phone: 914-206-9742

Email: [email protected]

SOURCE DJS Law Group LLP

Share this article

LOS ANGELES, Oct. 14, 2026/PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against York Space Systems, Inc. ("York" or "the Company") (NYSE: YSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of YSS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: Pursuant and/or traceable to the Company's January 2026 initial public offering ("IPO") and/or from January 29, 2026 to May 11, 2026

DEADLINE: October 30, 2026

If you are a shareholder who suffered a loss, click here to participate.

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. York failed to achieve fully functional mission and payload software before satellites were launched. The Company's contracts with the SDA were put at risk by this failure. Based on these facts, the Company's public statements were false and materially misleading throughout the IPO period. When the market learned the truth about York, investors suffered damages.

We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Join the case to recover your losses

WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Schall, Brown & Schwartz LLP

Brian Schall, Esq.,

Andrew Brown, Esq.,

David Schwartz, Esq.,

www.schallfirm.com

Office: 310-301-3335

[email protected]

SOURCE Schall, Brown & Schwartz LLP

Share this article

TULSA Abstracts at the 15th Interventional MRI Symposium Strengthen Real-World Evidence, Clinical Differentiation, and Platform Expansion Opportunity

TORONTO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that five abstracts presented at the 15th Interventional MRI (“iMRI”) Symposium in Boston, Massachusetts, reinforce the growing body of evidence supporting the real-world performance, clinical differentiation, and platform expansion potential of the TULSA Procedure™ performed using the TULSA-PRO® system.

Collectively, the presentations underscore three important dimensions of TULSA’s progress:

- Real-world validation: Findings from the CARE Registry and single-center experiences at Mayo Clinic in Florida and Rochester provide complementary evidence of TULSA outcomes across multiple treatment strategies and clinical settings.

- Clinical differentiation: Results from the CAPTAIN randomized controlled trial demonstrate statistically superior preservation of erectile function together with pad-free continence with the TULSA Procedure compared with robotic radical prostatectomy (“robotic RP”) at six months.

-

Platform expansion potential: Technical validation on the Siemens 0.55T Free.Max MRI platform demonstrates the feasibility of delivering TULSA on a lower-field-strength MRI system, potentially broadening equipment options and reducing infrastructure barriers for future TULSA-PRO® adoption.*

“These presentations illustrate how TULSA’s evidence base is evolving across the dimensions that matter most: meaningful functional outcomes for patients, reproducibility in routine clinical practice, and the potential to extend our technology to a broader range of iMRI platforms,” said Mathieu Burtnyk, Chief Technology Officer of Profound Medical. “Together, they reinforce the differentiation of TULSA-PRO and its potential to support broader clinical adoption over time.”

Mayo Clinic Florida: Real-World Clinical Experience (Page 88)

This analysis reports experience from one of the early U.S. centers to incorporate TULSA-PRO into routine clinical practice, including 58 patients with up to 4.5 years of follow-up.

Patients underwent a range of treatment approaches, including focal, hemi-gland, subtotal and whole-gland ablation. Serious adverse events were uncommon, with no strictures or fistulas reported. Reported functional outcomes included 100% pad-free continence, 94% leak-free continence and preservation of erections sufficient for penetration in 87.5% of men beyond 12 months.

Median PSA nadir was 0.9 ng/mL, and 12% of patients required secondary prostate cancer treatment during follow-up.

These findings add longer-term clinical experience from routine practice to the growing TULSA evidence base, complementing the randomized CAPTAIN trial and multicenter CARE Registry. The results should be interpreted in the context of the study’s single-center design, patient selection and treatment heterogeneity.

Mayo Clinic Rochester: Prospective Single-Center Study (Page 89)

This prospective study evaluated 41 patients with biopsy-proven localized prostate cancer treated with the TULSA Procedure.

Mean PSA declined from 7.7 ng/mL at baseline to approximately 2.3–2.6 ng/mL, representing a sustained reduction of approximately 62%–66% through one year. The safety profile was generally manageable, with most adverse events involving urinary or sexual function.

Biopsy-confirmed recurrence was reported in 22% of patients, including 12% with in-field recurrence and 10% with out-of-field recurrence. The authors concluded that the TULSA Procedure provided substantial, sustained PSA reduction with a generally favorable safety profile.

The findings add prospective evidence from another high-volume Mayo Clinic center, complementing the broader CARE Registry and the randomized CAPTAIN trial. Together, these studies contribute to a more comprehensive understanding of TULSA’s performance across clinical settings, while underscoring the importance of continued follow-up to characterize oncologic durability.

CARE Registry: Treatment Extent, PSA Response and Catheterization Duration (Page 43)

This analysis evaluated 197 patients treated with the TULSA Procedure across five centers, with a median follow-up of 24 months.

The findings demonstrate the flexibility of TULSA treatment planning, spanning focal, subtotal and whole-gland ablation. As expected, more extensive ablation was associated with deeper prostate-specific antigen (“PSA”) reductions: median PSA nadir was 0.23 ng/mL following whole-gland treatment, compared with 0.60 ng/mL after subtotal treatment and 1.10 ng/mL after focal treatment.

Biochemical recurrence rates did not differ significantly across treatment extents in this analysis. Less extensive treatments were also associated with shorter catheterization duration, decreasing from a median of 13.5 days following whole-gland treatment to seven days following subtotal or focal treatment.

These findings highlight a key feature of the TULSA Procedure: the ability to individualize treatment extent, balancing the objectives of malignant tissue ablation, functional preservation and recovery according to patient needs and clinical judgment.

CAPTAIN Randomized Trial: TULSA Procedure vs. Robotic Radical Prostatectomy — Six-Month Outcomes (Page 42)

CAPTAIN (A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants with Localized Prostate Cancer) is the first fully enrolled, multicenter randomized controlled trial directly comparing the TULSA Procedure with robotic RP in patients with localized intermediate-risk prostate cancer.

As previously reported, whole-gland TULSA demonstrated perioperative advantages over robotic RP, including no blood loss, no overnight hospitalization, faster recovery and earlier return to work. Hospitalizations for complications were also substantially lower with whole-gland TULSA than with robotic RP (0.7% versus 6.3%).

At the primary six-month functional endpoint, whole-gland TULSA achieved statistically superior outcomes, with patients more than twice as likely to preserve both erectile function and pad-free continence (risk ratio of 2.1; p=0.004). Whole-gland TULSA also demonstrated statistically superior preservation of flaccid penile length at one month compared with robotic RP.

While oncologic outcomes continue to mature, these findings provide important randomized evidence of whole-gland TULSA’s potential to improve peri-operative outcomes and preserve quality of life.

Technical Validation of TULSA on the Siemens 0.55T Free.Max MRI Platform (Page 87)

Investigators successfully validated the technical feasibility of the TULSA Procedure on Siemens’ 0.55T Free.Max MRI platform, a lower-field-strength MRI system that may potentially offer additional options for future TULSA-PRO installations.*

The evaluation incorporated new three-dimensional thermometry protocols that improved temperature-measurement precision by 40% compared with conventional approaches. Temperature-monitoring performance approached that of conventional 1.5T systems, with baseline uncertainty of approximately ±1.1°C. Prostate anatomy and surrounding structures remained clearly visible using biparametric MRI protocols, while simulated treatments demonstrated targeting accuracy of 1.0 ± 0.9 mm.

This technical validation represents a potentially important step toward expanding the range of MRI systems on which TULSA could be deployed. If translated into clinical and commercial use, compatibility with lower-cost, wide-bore MRI systems could help reduce equipment-related infrastructure barriers, broaden the potential TULSA-PRO installed-base opportunity and mitigate susceptibility artifacts associated with implants such as hip prostheses.

*Technical feasibility does not establish U.S. Food and Drug Administration clearance, clinical validation or commercial availability on this combined TULSA-PRO>Siemens 0.55T Free.Max platform. Any statements regarding future deployment remain subject to further development and applicable regulatory requirements.

Building the Evidence and Expanding the Opportunity

“Our focus is to translate TULSA’s clinical differentiation into a broader opportunity for patients, physicians and healthcare providers,” said Profound’s Chief Executive Officer and Chairman, Arun Menawat. “The evidence presented at this year’s iMRI Symposium reinforces the potential of the TULSA Procedure becoming a mainstream treatment modality across the entire prostate disease spectrum, while our technical progress on lower-field-strength Siemens Free.Max points to a potential path toward reducing potential infrastructure barriers to more widespread adoption over time.”

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis.

Neusoft Selected into 2026 IDC China FinTech Power Force 50 List

SHENYANG, China, Oct. 14, 2026 /PRNewswire/ -- Neusoft Corporation (SSE: 600718), an industry-leading information technology, products and solutions company for the global market, has been recognized in the 2026 IDC China FinTech Power Force 50 ranking, released recently by International Data Corporation (IDC).

The annual IDC China FinTech Power Force 50 selection specifically focuses on technology providers that have already achieved large-scale service capabilities and proven mature business models. This year's ranking evaluates candidates against four criteria: verified business maturity and market adoption, end-to-end full-link service delivery capabilities, independent technology development and regulatory compliance competence, as well as industry impact and ecosystem contribution.

Neusoft's inclusion in the list recognizes its leading industry competitiveness in core banking systems, AI-powered intelligent risk control, and look-through regulatory compliance solutions. It demonstrates that Neusoft, equipped with both self-developed underlying platforms and deep vertical industry expertise, has established itself as a reliable, trusted provider for mission-critical financial services operations.

Neusoft's competitive edge in financial risk management and compliance software is underpinned by the company's two cross-sector, highly transferable core strengths that have been refined over 30 years across multiple highly regulated industries: a proven full-stack capability to convert complex, distributed enterprise data into measurable business value, and field-validated expertise in deploying artificial intelligence responsibly with built-in governance.

As China's fintech industry enters deep-water development phase, the market has a growing demand for providers with robust underlying technology, deep understanding of both business and regulatory requirements, and a proven track record of building long-term partnerships. With three decades of accumulated data capabilities and AI implementation expertise, Neusoft stands out to meet the market demands, and is well-positioned to unlock new value growth opportunities in the period ahead.

For more information about Neusoft, please visit www.neusoft.com.

SOURCE Neusoft Corporation

Share this article

Slimmer Smart Glasses, Full Eye Tracking: Viewpointsystem Brings the Entire Pipeline to the Edge

- Viewpointsystem is the first to bring to market a complete image-based eye-tracking pipeline that runs directly on an ultra-low-power microcontroller (MCU) inside the glasses frame

- The MCU powers Viewpointsystem's compact, ready-to-integrate Digital Iris® Module, delivering 140 Hz eye tracking without requiring a powerful application processor

- Full edge processing reduces power consumption, heat and hardware requirements, enabling up to 15 times longer battery runtime and slimmer, lighter smart glasses

VIENNA, Oct. 14, 2026 /PRNewswire/ -- Viewpointsystem gives smart-glasses manufacturers (OEMs) a new way to add advanced eye tracking without compromising on battery life, heat or design. Until now, power consumption, heat generation and limited space have made it difficult to bring eye tracking into lightweight smart glasses. Viewpointsystem's new implementation of its Digital Iris Module, powered by an ultra-low-power Ensemble MCU from edge AI pioneer Alif Semiconductor, removes this hurdle: the market-ready module runs the entire image-based eye-tracking pipeline at 140 Hz directly inside the glasses frame.

This MCU-based architecture makes integration considerably easier: OEMs no longer need a high-end application processor for eye tracking, yet the module remains fully compatible with existing application processors. Thanks to its integrated neural processing unit (NPU) for efficient AI processing, the programmable MCU can also run additional AI-based functions. At the same time, the architecture lowers power and processing demands and keeps sensitive eye-camera images safely on the chip.

"Eye tracking belongs in smart glasses, and it has to fit into the thinnest, lightest designs. By moving the entire processing pipeline to the edge, we're giving smart-glasses OEMs the flexibility to integrate eye tracking across a wider range of designs, with or without a high-end application processor," said Nils Berger, CEO and Founder of Viewpointsystem.

How the Technology Works

Conventional eye-tracking systems typically transfer images from eye-facing cameras to a main application processor in the glasses or a connected device. Processing these image streams consumes power, generates heat and adds to system complexity – a particular challenge for compact, battery-powered eyewear.

Viewpointsystem's Digital Iris Module combines two optimally positioned eye-facing cameras with the MCU in a compact hardware unit designed to fit into the bridge of the glasses frame. The MCU handles the complete processing pipeline, from image preprocessing and NPU-accelerated gaze calculation to real-time detection of eye events such as blinks, fixations and saccades. Instead of transmitting camera images, it delivers ready-to-use gaze data for real-time attention and focus tracking, as well as applications assessing brain health, cognitive changes and neurological function.

Key Benefits for Smart-Glasses OEMs

- Lower power consumption, longer battery life: Performance measurements indicate up to 15 times longer battery runtime compared with conventional eye-tracking processing on a connected device. Reduced heat generation further supports compact, comfortable designs.

- Performance on the edge: The MCU delivers eye-tracking rates of 140 Hz, with the potential to reach up to 400 Hz depending on customer requirements and use cases. It also acquires and fuses data from additional on-board sensors, including an ambient light sensor, magnetometer, and accelerometer, directly on the edge, while freeing the main processor for other tasks or low-power states.

- Easy integration and design flexibility: The ready-to-integrate Digital Iris Module combines hardware and software, reduces development effort for OEMs, and can be adapted to fit different smart-glasses designs.

- Privacy and AI capabilities: Only gaze data leaves the MCU, keeping sensitive eye images on-chip. The programmable MCU can also support additional workloads, including AI-based functions.

"Viewpointsystem's implementation demonstrates how our Ensemble MCU can handle demanding real-time vision processing within the tight power and space constraints of smart glasses," said Mark Rootz, VP Global Marketing at Alif Semiconductor. "This is exactly what we built the Ensemble family for: real-time AI at the edge without the power and thermal overhead of an application processor."

The patented MCU-based solution now opens up new opportunities for eye tracking in smart glasses where power, space and processing constraints have so far ruled it out – from lightweight AI and AR glasses to display-less eyewear and specialized industrial applications.

- Picture is available at AP -

About Viewpointsystem

Viewpointsystem is a Vienna-based deep-tech company that develops and manufactures internationally recognized smart glasses with eye tracking for applications in manufacturing, transportation, research and defense. Its DIGITAL IRIS® technology enables smart-glasses OEMs to integrate advanced eye tracking into their products, paving the way for more intuitive human-computer interaction. Viewpointsystem is a member of the Qualcomm Partner Network and the AR Alliance. viewpointsystem.com

Media Contact

Jana Riethausen

PR & Corporate Communications

Viewpointsystem GmbH

+43 660 90 50 515

[email protected]

SOURCE Viewpointsystem

Share this article

FitVille Launches Rebound Nova Walking Shoes Featuring Triple-Density Cushioning and Wide-Fit Comfort

A new walking shoe collection blends Dyno Foam™ triple-density cushioning, ergonomic support, and improved traction, all in an everyday design.

NEWARK, Del., Oct. 14, 2026/PRNewswire/ -- FitVille has expanded its wide-fit footwear lineup with the new Rebound Nova Collection, featuring Dyno Foam™, a triple-density cushioning system designed to balance comfort, stability, and responsiveness for everyday walking.

Six Models, One Comfort-First Approach

The Rebound Nova Collection includes six models: Men's Rebound Apex, Rebound Nova, Rebound Nova Elite, Rebound Nova Edge, Rebound Nova Grand, and Rebound Summit.

With widths available up to 4E, the collection provides extra room around the forefoot and toes without compromising modern styling or support.

Dyno Foam™: Three Densities for Targeted Cushioning

Unlike earlier Rebound Core and Neo models, which use dual-density EVA foam, Rebound Nova introduces three foam densities: 53C, 55C, and 58C.

The softer 53C foam cushions the forefoot, the intermediate 55C layer supports smooth transitions, and the firmer 58C heel helps provide stability and impact control. Together, these densities create a more balanced cushioning experience.

Wide-Fit Engineering Meets Enhanced Traction

Rebound Nova combines its wider fit with a 3-in-1 Ergonomic Insole System designed for cushioning, ventilation, and arch support. Its Eight-Point Traction Outsole features eight strategically positioned support areas to improve ground contact.

According to FitVille's internal testing, the outsole delivers 20% more traction while reducing weight by 20%.

Modern Style for Everyday Movement

With streamlined silhouettes, clean details, and versatile colors, Rebound Nova brings a contemporary look to wide-fit walking shoes. The collection is designed for daily walks, shopping, work shifts, and extended periods of standing.

"FitVille has always focused on two things: creating footwear that accommodates the whole foot and finding better ways to deliver real comfort," said James D. Kuai, Founder and CEO of FitVille.

The Rebound Nova Collection combines FitVille's wide-fit expertise with upgraded cushioning and traction technology. All six models are available through FitVille's official website.

Founded in 2018, FitVille specializes in wide and therapeutic footwear for diabetes, bunions, arthritis, and plantar fasciitis. Combining American design with expert Asian manufacturing, its Comfort+™, PropelCore™, and ErgoFit™ technologies deliver durable support and comfort. Guided by "Liberate Your Toes with Comfortable Shoes," FitVille advances foot health worldwide.

"Press Release Service" should be linked to https://www.24-7pressrelease.com/.

SOURCE FitVille

Share this article